ANAPEN 0.3 MG / 0.3 ML
EPINEPHRINE : 0.3 MG / 0.3 ML · DIN 02306751 · ENDO OPERATIONS LTD.
Health Canada status: DORMANT
What is ANAPEN?
ANAPEN 0.3 MG / 0.3 ML contains EPINEPHRINE : 0.3 MG / 0.3 ML. It is listed in the Health Canada Drug Product Database under DIN 02306751, held by ENDO OPERATIONS LTD., supplied as SOLUTION for INTRAMUSCULAR administration. Health Canada currently lists it as dormant, status dated 19-Jan-2026. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ANAPEN used for?
Emergency treatment of anaphylactic reactions (Type I) in patients at increased risk for anaphylaxis, including history of anaphylactic reactions.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02306751 |
|---|---|
| Brand name | ANAPEN |
| Generic / active ingredient | EPINEPHRINE : 0.3 MG / 0.3 ML |
| Manufacturer | ENDO OPERATIONS LTD. |
| Strength | 0.3 MG / 0.3 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAMUSCULAR |
| Schedule | Ethical |
| ATC code | C01CA24 EPINEPHRINE |
| AHFS class | 12:12.12 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 19-Jan-2026 |
| Original market date | 2009-11-23 00:00:00 |
How is it administered?
Intramuscular injection into the anterolateral thigh. ANAPEN (0.3 mg) for patients ≥30 kg; ANAPEN JUNIOR (0.15 mg) for patients 15-30 kg. May repeat every 5-15 minutes if needed.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Table of Contents lists section 13, but text cuts off). Standard epinephrine storage is typically 15-25°C.
How is it supplied?
Unidose auto-injector containing 1.05 mL of solution (delivers a single 0.3 mL dose).
Contraindications
There are no absolute contraindications to the use of epinephrine in a life-threatening allergic situation.
Warnings and precautions
Emergency use only; seek medical care immediately. Do not inject into buttock, digits, hands, or feet. Risk of cerebral hemorrhage if injected IV. Contains sodium metabisulfite.
Is EPINEPHRINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Active — reported by PFIZER CANADA ULC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C01CA24 EPINEPHRINE. 7 of 29 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ADRENALIN | 1 MG | SOLUTION | SEARCHLIGHT PHARMA INC | MARKETED | DIN 00155357 |
| EPINEPHRINE INJECTION | 1 MG / 10 ML | SOLUTION | LABORATOIRE AGUETTANT | MARKETED | DIN 02521148 |
| EPINEPHRINE INJECTION USP | 1 MG / 1 ML | SOLUTION | HIKMA CANADA LIMITED | MARKETED | DIN 02435810 |
| EPINEPHRINE INJECTION USP | 1 MG / 10 ML | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 00710814 |
| EPINEPHRINE INJECTION USP | Strength | Solution | PFIZER CANADA ULC 17300 Trans-Canada Highway Kirkland Quebec Canada H9J 2M5 | MARKETED | DIN 00721891 |
| EPIPEN | 0.3 MG / 0.3 ML | SOLUTION | MYLAN SPECIALTY LP | MARKETED | DIN 00509558 |
| EPIPEN JR | 0.15 MG / 0.3 ML | SOLUTION | MYLAN SPECIALTY LP | MARKETED | DIN 00578657 |
| ADRENACLICK 0.15MG AUTO-INJECTOR | 0.15 MG / 0.15 ML | SOLUTION | AMEDRA PHARMACEUTICALS LLC | CANCELLED PRE MARKET | DIN 02354322 |
| ADRENACLICK 0.30MG AUTO-INJECTOR | 0.30 MG / 0.30 ML | SOLUTION | AMEDRA PHARMACEUTICALS LLC | CANCELLED PRE MARKET | DIN 02354330 |
| ALLERJECT | 0.15 MG / 0.15 ML | SOLUTION | VALEO PHARMA INC | CANCELLED POST MARKET | DIN 02382059 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.